SCHEMBL2395020

SCHEMBL2395020

CCOC(=O)CNc1ccc(Cl)cc1Oc1ccc(N)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.43
HPGD P15428 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 4/20 0.40
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.39
HTT P42858 1/20 0.39
LMNA P02545 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
TDP1 Q9NUW8 4/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
POLB P06746 1/20 0.39
PPIB P23284 1/20 0.39
PPIA P62937 1/20 0.39
PPID Q08752 1/20 0.39
PPIG Q13427 1/20 0.39
TSHR P16473 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2393320 0.84 PTGDR2 (0.47) GAAHPGDMEN1KMT2AALDH1A1
SCHEMBL2396776 0.83 LMNA (0.48) GAAMEN1KMT2AALDH1A1MAPT
SCHEMBL24460021 0.80 ALDH1A1 (0.56) GAAHPGDMEN1KMT2AALDH1A1
SCHEMBL13742135 0.75 MAPT (0.42) HPGDALDH1A1MAPTHTTLMNA
SCHEMBL2398375 0.74 L3MBTL1 (0.43) GAAHPGDMEN1KMT2AALDH1A1
SCHEMBL28596977 0.74 MEN1 (0.57) GAAHPGDMEN1KMT2AALDH1A1
SCHEMBL10487899 0.73 ALDH1A1 (0.56) GAAHPGDMEN1KMT2AALDH1A1
SCHEMBL1503919 0.73 NPSR1 (0.59) GAAHPGDMEN1KMT2AALDH1A1
SCHEMBL2395176 0.73 LMNA (0.45) GAAMEN1KMT2AALDH1A1MAPT
SCHEMBL2394415 0.72 CCR2 (0.45) GAAHPGDKDM4EHTTSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102557971-B Substituted acids for the treatment of respiratory diseases ASTRAZENECA AB 2015-06-17 CN disclosed
EP-1765768-B1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2013-11-06 EP disclosed
US-8022248-B2 3-[2-(3-Cyanophenoxy)-4-(trifluoromethyl)phenyl]propanoic acid;prostaglandin D2 inhibitor, orphan receptor CRTH2 antagonist; antiinflammatory, analgesic, antipyretic; respiratory system disorders: asthma and rhinitis; coupling amino/thio-phenyl derivatives with ester followed by hydrolysis to acid ASTRAZENECA AB (SE) 2011-09-20 US disclosed
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases ASTRAZENECA AB (SE) 2008-05-15 US disclosed
EP-1765768-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES AstraZeneca AB (SE) 2007-03-28 EP disclosed
WO-2006005909-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases HRH2, HRH1, HRH4 GAA 359/4885HPGD 700/4885MEN1 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.